Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 7/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.49 |
| ▸ | F13A1 | P00488 | 1/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | TGM1 | P22735 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 2/20 | 0.46 |
| ▸ | MMP3 | P08254 | 2/20 | 0.46 |
| ▸ | MMP7 | P09237 | 2/20 | 0.46 |
| ▸ | MMP9 | P14780 | 2/20 | 0.46 |
| ▸ | MMP13 | P45452 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2890129 | 0.85 | MMP1 (0.62) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL2886117 | 0.79 | MMP1 (0.62) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL6498571 | 0.76 | MMP1 (0.55) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL6628734 | 0.75 | LMNA (0.51) | — | |
| SCHEMBL2887777 | 0.73 | MMP1 (0.50) | KDM4EMMP1MMP3MMP7MMP9 | |
| SCHEMBL16635434 | 0.73 | ALDH1A1 (0.59) | KDM4E | |
| SCHEMBL15832928 | 0.73 | ALDH1A1 (0.59) | KDM4E | |
| SCHEMBL7559500 | 0.72 | LMNA (0.47) | AGTR2 | |
| SCHEMBL893543 | 0.71 | ALDH1A1 (0.66) | KDM4E | |
| SCHEMBL893545 | 0.71 | ALDH1A1 (0.66) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030139419-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | ASTRAZENECA AB (SE) | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139419-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | MMP13, MMP3, MMP2 | FKBP1A 982/4885HTR2A 127/4885KDM4E 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.